Evidence map›Paper›PMID 29620159›Full record

ArticleInternational journal of molecular medicine2018

FOXP3 expression is modulated by TGF‑β1/NOTCH1 pathway in human melanoma.

Eva Skarmoutsou, Valentina Bevelacqua, Fabio D' Amico, Angela Russo, Demetrios A Spandidos, Aurora Scalisi, Grazia Malaponte, Claudio Guarneri

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Eva SkarmoutsouDepartment of Biomedical and Biotechnological Science, University of Catania, 95124 Catania, Italy.
Valentina BevelacquaDepartment of Biomedical and Biotechnological Science, University of Catania, 95124 Catania, Italy.
Fabio D' AmicoDepartment of Biomedical and Biotechnological Science, University of Catania, 95124 Catania, Italy.
Angela RussoDepartment of Biomedical and Biotechnological Science, University of Catania, 95124 Catania, Italy.
Demetrios A SpandidosLaboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Crete, Greece.
Aurora ScalisiUnit of Oncologic Diseases, ASP‑Catania, 95100 Catania, Italy.
Grazia MalaponteResearch Unit of the Catania Section of the Italian League Against Cancer, 95122 Catania, Italy.
Claudio GuarneriDepartment of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98122 Messina, Italy.
University of Catania · ITUniversity of Crete · GRUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Forkhead box protein 3 (FOXP3) transcription factor is expressed by immune cells and several human cancers and is associated with tumor aggressiveness and unfavorable clinical outcomes. NOTCH and transforming growth factor‑β (TGF‑β) protumorigenic effects are mediated by FOXP3 expression in several cancer models; however, their interaction and role in melanoma is unknown. We investigated TGF‑β‑induced FOXP3 gene expression during NOTCH1 signaling inactivation. Primary (WM35) and metastatic melanoma (A375 and A2058) cell lines and normal melanocytes (NHEM) were used. FOXP3 subcellular distribution was evaluated by immuno-cytochemical analysis. Gene expression levels were assessed by reverse transcription‑quantitative polymerase chain reaction. Protein levels were assessed by western blot analysis. The γ‑secretase inhibitor (GSI) was used for NOTCH1 inhibition and recombinant human (rh)TGF‑β was used for melanoma cell stimulation. Cell proliferation and viability were respectively assessed by MTT and Trypan blue dye assays. FOXP3 mRNA and protein levels were progressively higher in WM35, A375 and A2058 cell lines compared to NHEM and their levels were further increased after stimulation with rh‑TGF‑β. TGF‑β‑mediated FOXP3 expression was mediated by NOTCH1 signaling. Inhibition of NOTCH1 with concomitant rh‑TGF‑β stimulation determined the reduction in gene expression and protein level of FOXP3. Finally, melanoma cell line proliferation and viability were reduced by NOTCH1 inhibition. The results show that nn increase in FOXP3 expression in metastatic melanoma cell lines is a potential marker of tumor aggressiveness and metastasis. NOTCH1 is a central mediator of TGF‑β‑mediated FOXP3 expression and NOTCH1 inhibition produces a significant reduction of melanoma cell proliferation and viability.

Indexed as

Signal TransductionAmyloid Precursor Protein SecretasesCell DeathCell Line, TumorCell ProliferationEnzyme InhibitorsForkhead Transcription FactorsHumansMelanomaReceptor, Notch1Transforming Growth Factor beta1Up-RegulationAmyloid Precursor Protein SecretasesEnzyme InhibitorsForkhead Transcription FactorsFOXP3 protein, humanNOTCH1 protein, humanReceptor, Notch1Transforming Growth Factor beta1

Identifiers

PMID29620159
PMCPMC5979787
OpenAlexW2795390430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.